BR112021006132A2 - compostos bifenil sulfonamida para o tratamento de doenças de colágeno tipo iv - Google Patents
compostos bifenil sulfonamida para o tratamento de doenças de colágeno tipo iv Download PDFInfo
- Publication number
- BR112021006132A2 BR112021006132A2 BR112021006132-0A BR112021006132A BR112021006132A2 BR 112021006132 A2 BR112021006132 A2 BR 112021006132A2 BR 112021006132 A BR112021006132 A BR 112021006132A BR 112021006132 A2 BR112021006132 A2 BR 112021006132A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- fact
- pharmaceutical composition
- compound
- alport
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862741270P | 2018-10-04 | 2018-10-04 | |
| US62/741,270 | 2018-10-04 | ||
| US201962853904P | 2019-05-29 | 2019-05-29 | |
| US62/853,904 | 2019-05-29 | ||
| US201962894559P | 2019-08-30 | 2019-08-30 | |
| US62/894,559 | 2019-08-30 | ||
| PCT/US2019/054559 WO2020072814A1 (en) | 2018-10-04 | 2019-10-03 | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021006132A2 true BR112021006132A2 (pt) | 2021-07-20 |
Family
ID=68318947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021006132-0A BR112021006132A2 (pt) | 2018-10-04 | 2019-10-03 | compostos bifenil sulfonamida para o tratamento de doenças de colágeno tipo iv |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11207299B2 (https=) |
| EP (1) | EP3860594B1 (https=) |
| JP (2) | JP7524167B2 (https=) |
| KR (1) | KR102902972B1 (https=) |
| CN (1) | CN113286587A (https=) |
| AU (1) | AU2019354784B2 (https=) |
| BR (1) | BR112021006132A2 (https=) |
| CA (1) | CA3114434A1 (https=) |
| ES (1) | ES3057657T3 (https=) |
| IL (1) | IL281965B1 (https=) |
| MA (1) | MA53817A (https=) |
| MX (1) | MX2021003606A (https=) |
| WO (1) | WO2020072814A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117017985A (zh) | 2016-10-13 | 2023-11-10 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
| WO2022246200A1 (en) * | 2021-05-21 | 2022-11-24 | Travere Therapeutics, Inc. | Methods of treating kidney diseases or disorders |
| WO2022266370A1 (en) * | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| HUP0104634A3 (en) | 1998-07-06 | 2002-11-28 | Bristol Myers Squibb Co | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| ATE339417T1 (de) | 1999-12-15 | 2006-10-15 | Bristol Myers Squibb Co | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten |
| WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2010135350A2 (en) | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| US9719981B2 (en) | 2012-08-17 | 2017-08-01 | Father Flanagan's Boys' Home | RAC1 inhibitors for the treatment of alport glomerular disease |
| CA2958585C (en) * | 2014-08-21 | 2024-01-09 | Stealth Biotherapeutics Corp | Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome |
| EP3515501A1 (en) * | 2016-09-19 | 2019-07-31 | Aten Porus Lifesciences | Cyclodextrin based polymers, methods, compositions and applications thereof |
| CN117017985A (zh) * | 2016-10-13 | 2023-11-10 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
| US20220048900A1 (en) | 2018-12-21 | 2022-02-17 | Travere Therapuetics, Inc. | Amorphous sparsentan compositions |
-
2019
- 2019-10-03 MA MA053817A patent/MA53817A/fr unknown
- 2019-10-03 BR BR112021006132-0A patent/BR112021006132A2/pt unknown
- 2019-10-03 EP EP19791401.3A patent/EP3860594B1/en active Active
- 2019-10-03 IL IL281965A patent/IL281965B1/en unknown
- 2019-10-03 JP JP2021518888A patent/JP7524167B2/ja active Active
- 2019-10-03 MX MX2021003606A patent/MX2021003606A/es unknown
- 2019-10-03 WO PCT/US2019/054559 patent/WO2020072814A1/en not_active Ceased
- 2019-10-03 AU AU2019354784A patent/AU2019354784B2/en active Active
- 2019-10-03 US US16/592,633 patent/US11207299B2/en active Active
- 2019-10-03 CN CN201980079773.4A patent/CN113286587A/zh active Pending
- 2019-10-03 KR KR1020217010358A patent/KR102902972B1/ko active Active
- 2019-10-03 ES ES19791401T patent/ES3057657T3/es active Active
- 2019-10-03 CA CA3114434A patent/CA3114434A1/en active Pending
-
2024
- 2024-07-17 JP JP2024114026A patent/JP2024133735A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7524167B2 (ja) | 2024-07-29 |
| MX2021003606A (es) | 2021-08-16 |
| US20200147050A1 (en) | 2020-05-14 |
| JP2024133735A (ja) | 2024-10-02 |
| MA53817A (fr) | 2021-08-11 |
| CN113286587A (zh) | 2021-08-20 |
| EP3860594B1 (en) | 2025-10-01 |
| CA3114434A1 (en) | 2020-04-09 |
| AU2019354784A1 (en) | 2021-04-15 |
| IL281965A (en) | 2021-05-31 |
| WO2020072814A1 (en) | 2020-04-09 |
| JP2022514152A (ja) | 2022-02-10 |
| AU2019354784B2 (en) | 2025-07-10 |
| IL281965B1 (en) | 2026-04-01 |
| US11207299B2 (en) | 2021-12-28 |
| ES3057657T3 (en) | 2026-03-03 |
| KR20210081338A (ko) | 2021-07-01 |
| KR102902972B1 (ko) | 2025-12-22 |
| EP3860594A1 (en) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102528435B1 (ko) | 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물 | |
| JP7082115B2 (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| JP2024133735A (ja) | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 | |
| KR20120047891A (ko) | Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 | |
| TW202112359A (zh) | sGC活化劑於治療眼科疾病之用途 | |
| CN109417016B (zh) | 用于治疗缺血-再灌注损伤的戊二酸化合物 | |
| KR20240158972A (ko) | 소세포 폐암의 치료 방법 | |
| WO2022246200A1 (en) | Methods of treating kidney diseases or disorders | |
| HK40059411B (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases | |
| HK40059411A (en) | Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases | |
| BRPI0713647A2 (pt) | formulações farmacêuticas e composições de um antagonista seletivo cxcr2 ou cxcr1 e métodos para o uso do mesmo visando o tratamento de distúrbios inflamatórios | |
| KR20260021653A (ko) | IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄 | |
| WO2025064688A1 (en) | Sparsentan for treating immunoglobulin a nephropathy (igan) | |
| CA3071096A1 (en) | Co-administration of minocycline and colistin to reduce acute kidney injury | |
| WO2024073672A1 (en) | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders | |
| BR122025008185A2 (pt) | Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo | |
| CN106176723A (zh) | 一种固体药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |